KRAS mutant-specific protein interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic regulation.

被引:0
|
作者
Hobbs, Guy Aaron [1 ]
Burge, Rachel [1 ]
Linke, Amanda [1 ]
Sundararaj, Kamala [1 ]
O'Bryan, John P. [1 ]
机构
[1] Med Univ South Carolina, Charleston, SC USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
B057
引用
收藏
页码:96 / 97
页数:2
相关论文
共 35 条
  • [1] KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function
    Sundararaj, Kamala
    Burge, Rachel
    Saberikashani, Samaneh
    Bialousow, Lucas
    Linke, Amanda
    Smith, Merissa
    Ostrowski, Michael C.
    O'Bryan, John P.
    Hobbs, G. Aaron
    CANCER RESEARCH, 2024, 84 (02)
  • [2] Regulation of MYC protein stability by mutant KRAS in pancreatic ductal adenocarcinoma
    Vaseva, Angelina V.
    Blake, Devon R.
    Azam, Salma H.
    Gilbert, Karim T.
    Pecot, Chad V.
    Pearce, Kenneth H.
    Herring, Laura E.
    Graves, Lee M.
    Houghton, Peter J.
    Der, Channing J.
    CANCER RESEARCH, 2017, 77
  • [3] Intrinsic resistance mechanisms to mutant KRAS specific inhibitor in KRAS mutated colorectal cancer
    Maruyama, Kohei
    Suzuki, Mai
    Ohhara, Tomoko
    Nagayama, Satoshi
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2023, 114 : 1210 - 1210
  • [4] Intrinsic resistance mechanisms to mutant KRAS specific inhibitor in KRAS mutated colorectal cancer
    Maruyama, Kohei
    Suzuki, Mai
    Ohhara, Tomoko
    Nagayama, Satoshi
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2023, 114 : 783 - 783
  • [5] A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
    Duan, Xiaohua
    Zhang, Tuo
    Feng, Lingling
    de Silva, Neranjan
    Greenspun, Benjamin
    Wang, Xing
    Moyer, Jenna
    Martin, M. Laura
    Chandwani, Rohit
    Elemento, Olivier
    Leach, Steven D.
    Evans, Todd
    Chen, Shuibing
    Pan, Fong Cheng
    CELL STEM CELL, 2024, 31 (01) : 71 - 88.e8
  • [6] Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance
    Steinbrunn, Torsten
    Shirasaki, Ryosuke
    Dashevsky, Olga
    Tang, Huihui
    Yamano, Shizuka
    Mizuno, Rin
    Sugihara, Takeru
    Teoh, Phaik Ju
    Leypoldt, Lisa B.
    Kaji, Mariko
    Sorrell, Jeffrey
    Glassner, Brian J.
    Simoes, Ricardo De Matos
    Christensen, James
    Mitsiades, Constantine S.
    BLOOD, 2023, 142
  • [7] Discovery of a sex-specific metabolic phenotype in KRAS mutant colorectal cancer
    Yan, Hong
    Cai, Yuping
    Shen, Xinyi
    Jain, Abhishek
    Paty, Philip B.
    Bosenberg, Marcus
    Khan, Sajid A.
    Johnson, Caroline
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer
    Schultz, Michelle A.
    Diaz, Andrew M.
    Smite, Sharon
    Lay, Anna R.
    DeCant, Brian
    McKinney, Ronald
    Mascarinas, Windel E.
    Xia, Yinglin
    Neumann, Carola
    Bentrem, David
    Dawson, David W.
    Grippo, Paul J.
    ONCOTARGET, 2017, 8 (54) : 92667 - 92681
  • [9] Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients
    Benesova, Lucie
    Halkova, Tereza
    Belsanova, Barbora
    Bunganic, Bohus
    Traboulsi, Eva
    Zavoral, Miroslav
    Minarik, Marek
    CANCER RESEARCH, 2016, 76
  • [10] Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition
    Steinbrunn, Torsten
    Shirasaki, Ryosuke
    Dashevsky, Olga
    Tang, Huihui
    Yamano, Shizuka
    Teoh, Phaik Ju
    Leypoldt, Lisa
    Sugihara, Takeru
    Mizuno, Rin
    Kaji, Mariko
    Sorrell, Jeffrey
    Glassner, Brian
    Simoes, Ricardo de Matos
    Christensen, James
    Mitsiades, Constantine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S244 - S244